Screening for Toxoplasmosis in Immunocompetent Adults
Routine screening for Toxoplasma gondii infection is NOT indicated in immunocompetent adults. The available evidence focuses exclusively on screening in specific high-risk populations—HIV-infected individuals, immunocompromised patients, and pregnant women—with no guideline recommendations supporting universal screening in healthy adults 1, 2, 3, 1.
Who Should Be Screened
HIV-Infected Individuals
- All HIV-infected persons should be tested for Toxoplasma IgG antibody soon after HIV diagnosis to detect latent infection 3, 1
- This identifies patients who need prophylaxis when CD4+ counts drop below 100 cells/µL
- Toxoplasma-seropositive patients with CD4+ <100 cells/µL require prophylaxis against toxoplasmic encephalitis (TE) 2, 3, 1
- TMP-SMZ given for PCP prophylaxis also provides protection against TE 2, 3
Pregnant Women
- HIV-infected pregnant women should undergo serologic testing for Toxoplasma 4
- This identifies women at risk of transmitting infection to the fetus
- HIV-infected pregnant women with evidence of primary toxoplasmic infection or active toxoplasmosis require specialist consultation 1, 3
- Infants born to HIV-infected, Toxoplasma-seropositive mothers should be evaluated for congenital toxoplasmosis 1, 4
Patients on Targeted Immunotherapies
- Emerging evidence suggests screening should be considered for patients starting biologics, small molecules, or CAR T-cell therapies 5
- Baseline screening identifies seropositive patients who may benefit from prophylaxis or pre-emptive strategies
- These therapies create an expanded immunocompromised population susceptible to reactivation
Severely Immunosuppressed Children
- HIV-infected children >12 months receiving PCP prophylaxis with agents other than TMP-SMZ or atovaquone should have serologic testing 1, 3
- Seropositive children require prophylaxis for both PCP and toxoplasmosis
Why Not Screen Immunocompetent Adults
The evidence is clear on this point:
- Toxoplasmosis in immunocompetent individuals is generally benign and asymptomatic 6, 7, 8
- Disease severity and clinical manifestations are directly tied to immune status 8
- All guideline recommendations from USPHS/IDSA focus exclusively on immunocompromised populations 1, 2, 3, 1
- No mortality or morbidity benefit exists for screening healthy adults
Key Clinical Pitfalls
Don't confuse exposure prevention with screening: All persons (including immunocompetent) should receive education about avoiding raw/undercooked meat, proper hand hygiene after handling cats/soil, and washing fruits/vegetables 3, 1
Recognize the immunocompromised spectrum: The definition of "immunocompetent" is evolving—patients on targeted immunotherapies may appear healthy but are functionally immunocompromised 5
Occupational exposures are different: Laboratory workers with accidental exposures to Toxoplasma require post-exposure management regardless of baseline immune status 9
The Bottom Line
Screen only when immune status warrants it: HIV infection with any CD4+ count, pregnancy in HIV-infected women, severe immunosuppression from any cause, or initiation of targeted immunotherapies. For truly immunocompetent adults without these risk factors, screening provides no clinical benefit and is not recommended by any major guideline.